Your browser doesn't support javascript.
loading
Prognostic value of oxidative phosphorylation-related genes in hepatocellular carcinoma.
Liu, Luzheng; Chen, Jiacheng; Ye, Fei; Chu, Fengran; Rao, Chaoluan; Wang, Yong; Yan, Yanggang; Wu, Jincai.
Affiliation
  • Liu L; Department of Interventional Radiology and Vascular Surgery, The Second Affiliated Hospital of Hainan Medical University, Haikou, 570100, Hainan Province, China.
  • Chen J; Department of Hepatobiliary and Pancreatic Surgery, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, 570311, Hainan Province, China.
  • Ye F; Department of Hepatobiliary and Pancreatic Surgery, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, 570311, Hainan Province, China.
  • Chu F; Department of Blood Cell Therapy, The Second Affiliated Hospital of Hainan Medical University, Haikou, 570100, Hainan Province, China.
  • Rao C; Department of Hepatobiliary and Pancreatic Surgery, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, 570311, Hainan Province, China.
  • Wang Y; Department of Nursing, The Second Affiliated Hospital of Hainan Medical University, Haikou, 570100, Hainan Province, China.
  • Yan Y; Department of Interventional Radiology and Vascular Surgery, The Second Affiliated Hospital of Hainan Medical University, Haikou, 570100, Hainan Province, China.
  • Wu J; Department of Interventional Radiology and Vascular Surgery, The Second Affiliated Hospital of Hainan Medical University, Haikou, 570100, Hainan Province, China. 564006105@qq.com.
Discov Oncol ; 15(1): 258, 2024 Jul 03.
Article in En | MEDLINE | ID: mdl-38960931
ABSTRACT

PURPOSE:

Hepatocellular carcinoma (HCC) is the most prevalent malignancies worldwide. Recently, oxidative phosphorylation (OXPHOS) has received extensive concern as an emerging target in antitumor therapy. However, the OXPHOS-involved underlying genes and clinical utilization in HCC remain worth exploring. The present research aimed to create an OXPHOS-relevant signature in HCC. PATIENTS AND

METHODS:

In this study, the prognostic signature genes linked with OXPHOS were identified, and prognostic models were built using least absolute shrinkage and selection operator (LASSO) cox regression analysis. Furthermore, the combination study of immune microenvironment and signature genes looked into the involvement of immune cells in signature-based genes in HCC. Following that, chemotherapeutic drug sensitivity and immunotherapy analysis was implemented to predict clinical efficacy in HCC patients. Finally, clinical samples were collected to measure the expression of OXPHOS-related signature genes.

RESULTS:

Following a series of screens, six prognostic signature genes related with OXPHOS were identified MRPS23, MPV17, MAPK3, IGF2BP2, CDK5, and IDH2, on which a risk model was built. The findings revealed a significant drop in the survival rate of HCC patients as their risk score increased. Meanwhile, independent prognostic study demonstrated that the risk score could accurately identify HCC patients. Immuno-microenvironmental correlation research suggested that the prognostic characteristics could serve as a reference index for both immunotherapy and chemotherapy. Finally, RT-qPCR exhibited a trend in signature gene expression that was consistent with the results.

CONCLUSION:

In this study, a total of six prognostic genes associated with OXPHOS were selected and a prognostic model was constructed, providing an essential reference for the study of OXPHOS in HCC.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Discov Oncol Year: 2024 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Discov Oncol Year: 2024 Document type: Article Affiliation country:
...